Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Sequenom, Anthem sales and marketing update

    Sequenom Inc. (NASDAQ:SQNM), San Diego, Calif. Anthem Inc. (NYSE:ANTM), Indianapolis, Ind. Business: Diagnostic Anthem Blue Cross and Blue Shield of Connecticut, Maine and New Hampshire will cover Sequenoms noninvasive …

    Published on 4/4/2016
  • Amicus Therapeutics sales and marketing update

    Amicus Therapeutics Inc. (NASDAQ:FOLD), Cranbury, N.J. Business: Endocrine/Metabolic Amicus began a reimbursed expanded access program for migalastat (AT1001) to treat Fabrys disease. The program will begin in France, …

    Published on 3/28/2016
  • Bayer sales and marketing update

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Cancer Germanys Institute for Quality and Efficiency in Health Care (IQWiG) issued an addendum to a second dossier assessment for Stivarga regorafenib from Bayer …

    Published on 3/28/2016
  • Cancer Genetics sales and marketing update

    Cancer Genetics Inc. (NASDAQ:CGIX), Rutherford, N.J. Business: Diagnostic Cancer Genetics launched the CLIA-certified Focus::Oncomine assay to detect biomarkers in solid tumors. The next-generation sequencing (NGS) …

    Published on 3/28/2016
  • Exelixis AG, Genentech, Roche sales and marketing update

    Exelixis AG (NASDAQ:EXEL), South San Francisco, Calif. Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Cancer Germanys Institute for Quality and Efficiency in …

    Published on 3/28/2016
  • J&J sales and marketing update

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cancer The U.K.s NICE issued final guidance recommending Zytiga abiraterone from Johnson & Johnson to treat metastatic castration-resistant prostate cancer (…

    Published on 3/28/2016
  • Novartis sales and marketing update

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Cancer Germanys Institute for Quality and Efficiency in Health Care (IQWiG) reversed a previous decision and found that Tafinlar dabrafenib plus Mekinist …

    Published on 3/28/2016
  • Regeneron, Bayer sales and marketing update

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Ophthalmic Germanys Institute for Quality and Efficiency in Health Care (IQWiG) said in a dossier …

    Published on 3/28/2016
  • Transgenomic sales and marketing update

    Transgenomic Inc. (NASDAQ:TBIO), Omaha, Neb. Business: Diagnostic Transgenomic launched the EGFR C797S Mutation Detection Assay worldwide for research use only. The company said the mutation is associated with …

    Published on 3/28/2016
  • Vertex sales and marketing update

    Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Boston, Mass. Business: Pulmonary The U.K.s NICE issued draft guidance recommending against the use of Orkambi ivacaftor/lumacaftor from Vertex to treat cystic fibrosis in …

    Published on 3/28/2016
  • Allergan sales and marketing update

    Allergan plc (NYSE:AGN), Dublin, Ireland Business: Neurology Allergan launched Vraylar cariprazine in the U.S. to treat schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I …

    Published on 3/21/2016
  • Amgen sales and marketing update

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Business: Cancer The U.K.s NICE issued draft guidance recommending against the use of Imlygic talimogene laherparepvec to treat unresectable melanoma that is regionally or…

    Published on 3/21/2016
  • MDxHealth sales and marketing update

    MDxHealth S.A. (Euronext:MDXH), Liege, Belgium Business: Diagnostic MDxHealth launched SelectMDx for Prostate Cancer in the U.S. to identify patients at risk of aggressive disease that may benefit from biopsy, MRI or …

    Published on 3/21/2016
  • Avita sales and marketing update

    Avita Medical Ltd. (ASX:AVH; OTCQX:AVMXY), Perth, Australia Business: Dermatology Avita launched ReGenerCell and ReNovaCell in Europe. Both autologous cell harvesting devices have CE Mark approval. ReGenerCell is …

    Published on 3/14/2016
  • Basilea sales and marketing update

    Basilea Pharmaceutica AG (SIX:BSLN), Basel, Switzerland Business: Infectious Basilea launched Cresemba isavuconazole in the U.K. and Germany to treat invasive aspergillosis and mucormycosis in patients for whom …

    Published on 3/14/2016
  • J&J sales and marketing update

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cancer The U.K.s NICE issued draft guidance recommending against the use of Imbruvica ibrutinib from Johnson & Johnson to treat chronic lymphocytic leukemia (…

    Published on 3/14/2016
  • MDxHealth sales and marketing update

    MDxHealth S.A. (Euronext:MDXH), Liege, Belgium Business: Diagnostic The National Comprehensive Cancer Network (NCCN) guidelines will include MDxHealths ConfirmMDx for Prostate Cancer for early detection of prostate …

    Published on 3/14/2016
  • Merck, VA sales and marketing update

    Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. U.S. Department of Veterans Affairs, Washington, D.C. Business: Infectious Merck said the U.S. Department of Veterans Affairs added Zepatier grazoprevir/elbasvir (MK-5172/MK…

    Published on 3/14/2016
  • Novocure, Humana sales and marketing update

    Novocure Ltd. (NASDAQ:NVCR), Isle of Jersey Humana Inc. (NYSE:HUM), Louisville, Ky. Business: Cancer Novocure said it received a positive coverage decision from Humana for Optune to treat newly diagnosed glioblastoma …

    Published on 3/14/2016
  • Otonomy sales and marketing update

    Otonomy Inc. (NASDAQ:OTIC), San Diego, Calif. Business: Infectious Otonomy launched Otiprio ciprofloxacin otic suspension in the U.S. to treat pediatric patients with bilateral otitis media with effusion undergoing …

    Published on 3/14/2016
  • Biocept sales and marketing update

    Biocept Inc. (NASDAQ:BIOC), San Diego, Calif. Business: Diagnostic Biocept said U.S. healthcare PPO network Prime Health Services Inc. will cover Biocepts liquid biopsy tests. Biocept said the deal expands the total …

    Published on 3/7/2016
  • UCB sales and marketing update

    UCB Group (Euronext:UCB), Brussels, Belgium Business: Neurology UCB launched Briviact brivaracetam in the U.K. as an adjunct therapy to treat partial-onset seizures in epileptics ages 16 and older. The company said the …

    Published on 3/7/2016
  • Endo sales and marketing update

    Endo International plc (NASDAQ:ENDP; TSX:ENL), Dublin, Ireland Business: Neurology Endo launched Belbuca buprenorphine in the U.S. to manage pain severe enough to require daily, around-the-clock, long-term opioid …

    Published on 2/29/2016
  • Grifols, Immundiagnostik, Theradiag sales and marketing update

    Grifols S.A. (Madrid:GRF; NASDAQ:GRFS), Barcelona, Spain Immundiagnostik AG, Bensheim, Germany Theradiag S.A. (Euronext:ALTER), Marne La Vallee, France Business: Autoimmune The U.K.s NICE issued diagnostics guidance …

    Published on 2/29/2016
  • JCR Pharmaceuticals sales and marketing update

    JCR Pharmaceuticals Co. Ltd. (Tokyo:4552), Ashiya, Japan Business: Transplant JCR launched Temcell HS (JR-031) in Japan to treat acute graft-versus-host disease (GvHD). The companies said the product, which comprises …

    Published on 2/29/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993